This opportunity funds early to definitive clinical trials testing drugs, devices, biologics, procedures, behavioral, social, economic, health services, or other biomedical or non-pharmacological interventions. The R61/R33 award mechanism supports a bi-phasic, milestone-driven approach with planning in the R61 phase and clinical trial execution in the R33 phase, for a maximum of 7 years. Applicants should align trials with NIH research missions and have expertise in clinical trial design and implementation.
Eligible applicants include a broad range of organizations such as state, county, city governments, tribal governments, public and private institutions of higher education, nonprofits, for-profit organizations, small businesses, federal agencies, U.S. territories, and foreign institutions. Specific
